What is the AQST stock price?

Aquestive Therapeutics, Inc. (AQST) last available close: $3.88, as of 11/3/26. Prices on Cylvex may be delayed.

How many analyst price targets for AQST were reached?

1 of 7 published price targets for AQST were reached within 12 months (14% reached); 3 are still open. Counts only — firm names and target values are shown to signed-in members.

How many firms publish price targets or ratings on AQST?

8 firms have published price targets or ratings on AQST that Cylvex tracks. Counts only — firm names and target values are shown to signed-in members.

Is this investment advice?

No. Cylvex is an educational and informational platform; nothing on this page is investment, financial or trading advice. Past analyst targets do not predict future results.

NASDAQ

Updated Nov 3, 7:59 PM ET

AQST

Aquestive Therapeutics, Inc.

$3.77CS band Caution

+$0.11 (2.92%) At close $3.88 · Today

☾After Hours −$0.11 (2.81%) Nov 3, 7:59 PM ET

About AQST

Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif, and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.

News

1 latest

No direct coverage yet · Showing articles that mention AQST

Thu, Oct 15

GlobeNewswire Inc.10/15/26

Aquestive Therapeutics Announces FDA Acceptance of Anaphylm™ NDA Resubmission and PDUFA Goal Date of March 16, 2027

Aquestive Therapeutics announced that the FDA has accepted its resubmission of the New Drug Application (NDA) for Anaphylm™ (dibutepinephrine) sublingual film for treating Type I allergic reactions and anaphylaxis. The FDA assigned a PDUFA goal date of March 16, 2027, classified as a Class 2 response.

Headlines open the publisher's site.